Moclobemide — Placebo‐controlled trials

  title={Moclobemide — Placebo‐controlled trials},
  author={Trevor Silverstone},
  journal={International Clinical Psychopharmacology},
  • T. Silverstone
  • Published 1993
  • Medicine
  • International Clinical Psychopharmacology
In this paper, three placebo-controlled trials of moclobemide, and four three-way comparison trials of moclobemide, placebo and one of the standard tricyclic antidepressants, imipramine, clomipramine, or amitriptyline, are reviewed. The results of the placebo-controlled trials indicate that about twice as many of the patients receiving moclobemide showed a marked improvement during a four-week treatment period, as compared with patients receiving placebo. Of the three-way trials, two studies… Expand
A controlled double-blind trial of moclobemide and imipramine in the treatment of depression.
No difference in antidepressive efficacy between the two drugs, but imipramine had more anticholinergic side-effects and neither drug had significant effects on pulse rate, blood pressure, weight changes or blood chemistry. Expand
Moclobemide and fluoxetine in atypical depression: a double-blind trial.
It is suggested that patients suffering from atypical depression may respond more favourably to moclobemide than to fluoxetine treatment. Expand
Clinical pharmacology of moclobemide during chronic administration of high doses to healthy subjects
The maximum tolerated dose of moclobemide in healthy subjects is 600”mg b.i.d. provided the tyramine content in a meal is not higher than 50 mg, and the incidence and intensity of adverse events was dose-dependent. Expand
A comparison of the efficacy and tolerability of moclobemide given as a single daily dose or in three divided doses per day for the treatment of patients with a major depressive episode (DSM-III-R)
This was a prospective, double-blind, randomized, multicenter trial comparing moclobemide once daily (OD) with three times daily (TDS) dosing and efficacies were found not to differ significantly. Expand
Efficacy and tolerability of moclobemide in bulimia nervosa: a placebo-controlled trial
The study indicates that moclobemide 600 mg pro die is not efficacious in bulimia nervosa, but it can be safely administered, even to young subjects, at a very high risk of consuming large amounts of tyramine-rich foods without dietary restrictions. Expand
Moclobemide versus fluoxetine for a major depressive episode
Doubling the low dosage in non-responders after 3 weeks resulted in a statistically significant improvement of CGI in the moclobemide group by comparison with the fluoxetine group at study end, suggesting that 600 mg moclopemide/day can still improve the patient's condition, while 40 mg fluoxettine/day does not. Expand
Moclobemide twice daily in the treatment of major depressive episode: a double-blind, multicenter comparison with different three-times-daily dosage schedules.
Tolerability was rated "good" or "excellent" in 94% of patients, and there was no appreciable change in vital signs in any of the treatment groups, suggesting that twice-daily moclobemide 150 mg b.i.d. is the optimal initial schedule for treatment of depression. Expand
Moclobemide versus fluoxetine for double depression: a randomized double-blind study.
The results suggest that moclobemide and fluoxetine are equally well tolerated and at least similar in efficacy in double depression, and evidence that mclobemides may be more effective requires confirmation in a larger comparative study incorporating a placebo control group. Expand
A Risk-Benefit Assessment of Moclobemide in the Treatment of Depressive Disorders
SummaryMoclobemide, a novel benzamide, is a reversible inhibitor of monoamine oxidase-A (RIMA). It has been extensively evaluated in the treatment of a wide spectrum of depressive disorders.Expand
Efficacy of tianeptine in major depressive disorders with or without melancholia
  • D. Ginestet
  • Medicine, Psychology
  • European Neuropsychopharmacology
  • 1997
The efficacy of tianeptine in the treatment of major depressive episodes was assessed in three double-blind placebo-controlled studies. In a first double-blind study comparing tianeptine (37.5Expand